Abstract:
The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies.
Abstract:
A rolling circle DNA replicon which replicates in a host eukaryotic cell is disclosed which has a truncated replication cycle. The rolling circle DNA replicon comprises the following elements present on the same DNA molecule. It contains a Rep gene open reading frame from a virus belonging to the viral taxonomic families Geminiviridae, Circoviridae or genus Nanovirus . The Rep gene open reading frame is placed under transcriptional control of a promoter, which is placed 5' of the gene. Any sequences that are required to be present in cis on the rolling circle DNA replicon in order that the Rep protein might promote replication of the rolling circle DNA replicon are included. An expression cassette for expression of an ancillary protein that is capable of creating a cellular environment permissive for replication of the rolling circle DNA replicon in the host cell of interest is also included. At least one expression cassette with an RNA polymerase II promoter, a multiple cloning site, and transcription termination and polyadenylation signals suitable for transcription of RNA molecules not normally intrinsic to a geminiviral, circoviral or nanoviral genome is also included.
Abstract:
Described are rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated with cancer and autoimmune diseases that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity.
Abstract:
The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.
Abstract:
The invention relates to a new group of viruses, designated SVI. Isolated SVI viruses, polynucleotides and proteins from SVI viruses, and antibodies which bind SVI virus and SVI viral proteins are provided. The polynucleotides, proteins, and antibodies of the invention may be used to detect SVI virus or infection by SVI virus in a susceptible individual. Additionally, polynucleotides of the invention may be inserted into recombinant expression vectors recombinant production of viral proteins.
Abstract:
Beschrieben werden DNA-Sequenzen, die das Genom eines Tumorassoziierten TT-Virus umfassen, oder Fragmente davon. Die vorliegende Erfindung betrifft ferner von diesen DNA-Sequenzen kodierte Proteine, gegen diese Proteine gerichtete Antikörper sowie gegen mRNAs gerichtete Ribozyme und Antisense-RNAs und schliesslich deren Verwendung in Diagnose und Therapie. Die vorliegende Erfindung betrifft auch zur Diagnose geeignete Reagenzien enthaltende Kits, z.B. Antikörper enthaltende Kits.
Abstract:
The invention relates to a new group of viruses, designated SVI. Isolated SVI viruses, polynucleotides and proteins from SVI viruses, and antibodies which bind SVI virus and SVI viral proteins are provided. The polynucleotides, proteins, and antibodies of the invention may be used to detect SVI virus or infection by SVI virus in a susceptible individual. Additionally, polynucleotides of the invention may be inserted into recombinant expression vectors recombinant production of viral proteins.
Abstract:
A rolling circle DNA replicon which replicates in a host eukaryotic cell is disclosed which has a truncated replication cycle. The rolling circle DNA replicon comprises the following elements present on the same DNA molecule. It contains a Rep gene open reading frame from a virus belonging to the viral taxonomic families Geminiviridae, Circoviridae or genus Nanovirus . The Rep gene open reading frame is placed under transcriptional control of a promoter, which is placed 5' of the gene. Any sequences that are required to be present in cis on the rolling circle DNA replicon in order that the Rep protein might promote replication of the rolling circle DNA replicon are included. An expression cassette for expression of an ancillary protein that is capable of creating a cellular environment permissive for replication of the rolling circle DNA replicon in the host cell of interest is also included. At least one expression cassette with an RNA polymerase II promoter, a multiple cloning site, and transcription termination and polyadenylation signals suitable for transcription of RNA molecules not normally intrinsic to a geminiviral, circoviral or nanoviral genome is also included.
Abstract:
The present invention relates to a nucleic acid molecule representing the genome of a virus/viral agent, said nucleic acid molecule having at least one of the following features: (a) it contains at least one open reading frame (ORF) which encodes a polypeptide having an amino acid sequence disclosed herein; (b) it comprises a DNA sequence as described herein; (c) it hybridizes preferably under stringent conditions to the complementary strand of the nucleic acid molecule described herein, but not to the complementary strand of the genome of TT virus; (d) it is degenerate with respect to the hybridizing nucleic acid molecule; (e) it is at least 60 % identical with the nucleic acid molecule representing the genome of the virus/viral agent of the invention; and (f) parts of it can be amplified under suitable conditions by PCR employing primers as defined herein. The invention further relates to vectors comprising said nucleic acid molecule, methods of producing (poly)peptide(s) encoded by said nucleic acid molecule, to viruses/viral agents carrying a genome represented by said nucleic acid molecule and antibodies to said (poly)peptide(s) and/or said viruses/viral agents. Additionally, the invention relates to compositions, preferably pharmaceutical compositions, vaccines, diagnostics and diagnostic kits comprising or employing the compounds of the invention.
Abstract:
The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.